Publications by authors named "A Viudez"
Article Synopsis
- Precision medicine is changing how we treat cancer, but many patients still lack access to the necessary genetic testing and treatments.
- A study in Spain examined how providing free RNA sequencing tests impacted the treatment of solid cancer patients who had already failed standard therapies, analyzing samples from 395 patients.
- The results showed actionable genetic alterations in 14.4% of patients, leading to limited use of targeted therapies, highlighting a need for better access to comprehensive molecular testing and personalized treatments.
Pancreatic ductal adenocarcinoma represents one of the solid tumors showing the worst prognosis worldwide, with a high recurrence rate after adjuvant or neoadjuvant therapy. Circulating tumor DNA analysis raised as a promising non-invasive tool to characterize tumor genomics and to assess treatment response. In this study, surgical tumor tissue and sequential blood samples were analyzed by next-generation sequencing and were correlated with clinical and pathological characteristics.
View Article and Find Full Text PDFArticle Synopsis
- Pancreatic ductal adenocarcinoma (PDAC) is a deadly cancer with late diagnoses and ineffective treatments, making surgery the only potential cure for early-stage patients.
- Recent research found that splicing machinery components, particularly PRPF8 and RBMX, are dysregulated in PDAC, correlating with worse patient outcomes and tumor characteristics.
- Modulating these splicing factors in cancer cell lines normalized their expression levels and reduced tumor-related features, suggesting they could be potential targets for new therapies in PDAC.
Background: Identification of predictive biomarkers to Immune checkpoint inhibitors (ICIs) in head and neck cancer (HNSCC) is an unmet need.
Methods: This was a prospective observational study including 25 patients with HNSCC treated with immunotherapy or chemotherapy after a prior platinum-based regimen. Low density neutrophils (LDNs) and serum markers were analyzed.
Single immune checkpoint blockade in advanced neuroendocrine neoplasms (NENs) shows limited efficacy; dual checkpoint blockade may improve treatment activity. Dune (NCT03095274) is a non-randomized controlled multicohort phase II clinical trial evaluating durvalumab plus tremelimumab activity and safety in advanced NENs. This study included 123 patients presenting between 2017 and 2019 with typical/atypical lung carcinoids (Cohort 1), G1/2 gastrointestinal (Cohort 2), G1/2 pancreatic (Cohort 3) and G3 gastroenteropancreatic (GEP) (Cohort 4) NENs; who progressed to standard therapies.
View Article and Find Full Text PDF